While relatively little is known about the role of Tregs for the efficiency of anti-leukemic immunity in AML [16, 17], several other immunosuppressive pathways of relevance to the course of disease have been described [18–20] including immunosuppression exerted by NOX2-derived reactive oxygen species (ROS) released from myeloid cells [21]. Here, CYBB is linked to acute myeloid leukemia.